{"url_path":"/sec/cpix/8-k/2026-09-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000068-index.html","accession_number":"0001087294-26-000068","cik":"0001087294","ticker":"CPIX","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000068-index.html","primary_entity_key":"0001087294","primary_entity_name":"CUMBERLAND PHARMACEUTICALS INC"},"word_count":397,"has_tables":true,"body_markdown":"cpix-20260421\n0001087294false00010872942026-04-212026-04-21\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 8-K/A\n\nCURRENT REPORT\n\nPursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934\n\nApril 21, 2026 (April 21, 2026)\n\nDate of Report (date of earliest event reported)\n\nCUMBERLAND PHARMACEUTICALS INC.\n\n(Exact name of registrant as specified in its charter)\n\nTennessee\n001-33637\n62-1765329\n\n(State or other jurisdiction of incorporation or organization)\n\n(Commission File Number)\n\n(I.R.S. Employer Identification No.)\n\n1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203\n\n(Address of Principal Executive Offices)\n\n(615) 255-0068\n\nRegistrant's telephone number, including area code\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock, no par valueCPIXNASDAQ Global Select Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nEXPLANATORY NOTE\n\nOn April 24, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or \"Cumberland\") filed a Current Report on Form 8-K (the “Original Report”) to report on, among other matters, the results of the advisory vote of the shareholders on the frequency of future advisory votes in compensation of the Company's named executive officers. This Current Report on Form 8-K/A updates information provided on the Original Report, relating to disclosures made under Item 5.07, Submission of Matters to a Vote of Security Holders associated with the Cumberland Pharmaceuticals Inc. Annual Meeting of Shareholders held on April 21, 2026 (the “2026 Annual Meeting”)."}